EDAP Reports Third Quarter 2025 Financial Results
EDAP (Nasdaq: EDAP) reported third-quarter 2025 results on November 6, 2025, with total revenue €13.9M (US $16.1M), up 6% year over year. The HIFU business drove growth: Q3 HIFU revenue was €6.7M (US $7.7M), +49% YoY, supported by six Focal One system sales and a 15% rise in U.S. procedures. System placements rose 167% YoY. Gross profit was €6.0M and gross margin improved to 43%. Q3 net loss narrowed to €5.0M (loss €0.13/share). The company closed a €36M EIB credit facility (first tranche €11M received) to support Focal One expansion and reiterated 2025 guidance for core HIFU revenue growth of 26–34%.
EDAP (Nasdaq: EDAP) ha riportato i risultati del terzo trimestre 2025 il 6 novembre 2025, con ricavi totali di €13,9 M (US $16,1 M), in aumento del 6% su base annua. Il business HIFU ha trainato la crescita: i ricavi HIFU del Q3 sono stati di €6,7 M (US $7,7 M), +49% YoY, supportati da sei vendite di sistemi Focal One e da un incremento del 15% delle procedure negli Stati Uniti. Le installazioni di sistemi sono aumentate del 167% YoY. L’utile lordo è stato di €6,0 M e la margine lordo è migliorata al 43%. La perdita netta del Q3 si è ridotta a €5,0 M (perdita di €0,13/azione). L’azienda ha chiuso una linea di credito EIB da €36 M (prima trancia di €11 M ricevuta) per supportare l’espansione di Focal One e ha riaffermato le previsioni 2025 per una crescita dei ricavi core HIFU pari al 26–34%.
EDAP (Nasdaq: EDAP) reportó los resultados del tercer trimestre de 2025 el 6 de noviembre de 2025, con ingresos totales de €13,9 M (US $16,1 M), un incremento del 6% interanual. El negocio de HIFU impulsó el crecimiento: los ingresos de HIFU en el 3T fueron de €6,7 M (US $7,7 M), +49% interanual, apoyados por seis ventas del sistema Focal One y un aumento del 15% en los procedimientos en EE. UU. Las colocaciones de sistemas aumentaron 167% interanual. La ganancia bruta fue de €6,0 M y el margen bruto mejoró a 43%. La pérdida neta del 3T se redujo a €5,0 M (pérdida de €0,13 por acción). La empresa cerró una línea de crédito EIB de €36 M (la primera tranco de €11 M recibida) para apoyar la expansión de Focal One y reiteró las perspectivas para 2025 de un crecimiento de ingresos centrales de HIFU del 26–34%.
EDAP (Nasdaq: EDAP)는 2025년 11월 6일 2025년 3분기 실적을 발표했고, 총매출액은 €13,9M (미화 $16.1M)로 전년 대비 6% 증가했습니다. HIFU 사업이 성장의 추진력: 3분기 HIFU 매출은 €6,7M (US $7,7M), 전년 대비 49% 증가, Focal One 시스템 6대 판매와 미국 내 시술 15% 증가에 힘입었습니다. 시스템 설치 역시 전년 대비 167% 증가했습니다. 매출총이익은 €6,0M이고 총이익률은 43%로 개선되었습니다. 3분기 순손실은 €5,0M으로 축소되었고 주당 손실은 €0.13였습니다. 회사는 Focal One 확장을 위한 €36M EIB 신용한도를 체결했으며(첫 번째 분할 €11M 수령), 2025년 핵심 HIFU 매출 성장 가이던스를 26–34%로 재확인했습니다.
EDAP (Nasdaq: EDAP) a publié les résultats du troisième trimestre 2025 le 6 novembre 2025, avec un chiffre d’affaires total de 13,9 M€ (16,1 M$), en hausse de 6% sur un an. L’activité HIFU a conduit la croissance: les revenus HIFU du T3 s’élevaient à €6,7 M (7,7 M$), +49% year-over-year, soutenus par six ventes du système Focal One et une hausse de 15% des procédures aux États‑Unis. Les installations de systèmes ont augmenté de 167% YoY. Le bénéfice brut était de €6,0 M et la marge brute s’est améliorée à 43%. La perte nette du T3 s’est réduite à €5,0 M (perte de €0,13 par action). L’entreprise a conclu une ligne de crédit EIB de €36 M (première tranche reçue de €11 M) pour soutenir l’expansion de Focal One et a réitéré les prévisions 2025 pour une croissance du chiffre d’affaires principal HIFU de 26–34%.
EDAP (Nasdaq: EDAP) berichtete am 6. November 2025 über die Ergebnisse des dritten Quartals 2025, mit einem Gesamtumsatz von 13,9 Mio. € (US$ 16,1 Mio.), einem Anstieg von 6% gegenüber dem Vorjahr. Das HIFU-Geschäft beflügelte das Wachstum: Der Q3-HIFU-Umsatz betrug €6,7 Mio. (US$ 7,7 Mio.), +49% YoY, unterstützt durch sechs Focal One-Systemverkäufe und einen Anstieg der US-Verfahren um 15%. Systemplatzierungen stiegen um 167% YoY. Der Bruttogewinn betrug €6,0 Mio., die Bruttomarge improved auf 43%. Der Nettoverlust im Q3 vergrößerte sich nicht, sondern verringerte sich auf €5,0 Mio. (Verlust von €0,13 pro Aktie). Das Unternehmen schloss eine EIB-Kreditfazilität über €36 Mio. ab (erste Tranche €11 Mio. erhalten) zur Unterstützung der Focal-One-Expansion und bestätigte die Guidance für 2025 für ein Kern-HIFU-Umsatzwachstum von 26–34%.
EDAP (Nasdaq: EDAP) أعلنت عن نتائج الربع الثالث من عام 2025 في 6 نوفمبر 2025, مع إجمالي الإيرادات 13,9 مليون يورو (16,1 مليون دولار أمريكي)، بارتفاع قدره 6% على أساس سنوي. قاد قطاع HIFU النمو: جاءت إيرادات HIFU للربع الثالث تبلغ €6,7 مليون (7,7 مليون دولار)، بزيادة 49% سنويًا، مدعومة ببيع ستة أنظمة Focal One وارتفاع بنسبة 15% في الإجراءات في الولايات المتحدة. ارتفعت عمليات تركيب الأنظمة بنسبة 167% سنويًا. بلغ إجمالي الربح €6,0 مليون وتحسّنت الهامش الإجمالي إلى 43%. تقلصت الخسارة الصافية للربع الثالث إلى €5,0 مليون (خسارة €0,13 للسهم). أغلقت الشركة تسهيلات ائتمانية من بنك الاستثمار الأوروبي بقيمة €36 مليون (تم استلام الشريحة الأولى بقيمة €11 مليون) لدعم توسيع Focal One وأعادت التأكيد على توجيهات 2025 لنمو إيرادات HIFU الأساسية بنسبة 26–34%.
- HIFU revenue +49% year-over-year in Q3
- Focal One placements +167% year-over-year in Q3
- U.S. procedures +15% year-over-year in Q3
- Gross margin improved to 43% in Q3
- €36M EIB credit facility closed; €11M first tranche deposited
- Q3 net loss narrowed to €5.0M (€0.13 per share)
- Non-core (ESWL/distribution) Q3 revenue declined €1.4M (≈16%) year-over-year
- Cash and cash equivalents declined from €16.3M (June 30) to €10.6M (Sept 30)
- Company remains operating loss negative at €4.9M in Q3
- Nine-month total revenue down 0.7% year-over-year to €43.5M
Insights
EDAP shows accelerating HIFU growth, improving margins and strengthened liquidity via an EIB credit facility — near-term outlook bright for Focal One.
Revenue gains came from the core HIFU franchise: HIFU revenue rose to
Key dependencies include sustained system placements and procedure adoption, reimbursement and hospital uptake in the U.S., and execution of commercial and clinical programs. Liquidity improved with a
Watch Focal One placements and U.S. procedure trend lines over the next 1–4 quarters, margin trajectory and absorption of fixed costs, and the timing/availability of remaining EIB tranches; the reiterated 2025 guidance (
EDAP Reports Third Quarter 2025 Financial Results
49% YoY HIFU Revenue Growth, Driven by Increased Focal One® Sales and U.S. Procedure Volumes167% YoY Growth in Focal One System Placements15% YoY Growth in U.S. Focal One HIFU Procedures- Company to Host Conference Call and Webcast on November 6 at 8:30 a.m. ET
AUSTIN, Texas, November 6, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the third quarter of 2025.
“Our record-breaking third-quarter revenue performance reflects the continued strong demand for our leading Focal One Robotic HIFU platform, with system placements increasing
“We have also made notable progress strengthening our balance sheet. As announced last month, we finalized an agreement with the European Investment Bank for a
Business Update
- On October 20, 2025, the Company announced the closing of a
€36 million credit facility with the European Investment Bank (EIB). Proceeds from this financing will support the continued expansion of the Company’s Focal One® Robotic HIFU platform in Focal Therapy, the fastest-growing treatment category for early-stage prostate cancer and accelerate the development of new clinical indications. - On September 30, 2025, the Company highlighted its Focal One Prostate Cancer Awareness Month campaign, featuring national television coverage on Friday, September 26, which reached millions of viewers nationwide. The segment, which included an interview with a patient treated with Focal One, aired during Health Uncensored with Dr. Drew on the Lifetime Network, providing unprecedented exposure and allowing audiences across the United States to learn about Focal One. In addition, the Company conducted multiple patient-education events and partnered with hospitals and practices nationwide to raise awareness through a range of local outreach activities.
- On September 16, 2025, the Company announced that it was honored with the 2025 Industry Award for Innovations in Endourological Instrumentation by the Endourological Society, recognizing its groundbreaking work with the Focal One High-Intensity Focused Ultrasound (HIFU) platform. Focal One is the first Focal Therapy technology to receive this distinguished award. Presented annually to an individual or organization that has made outstanding contributions to the field of urology, the award was conferred during the 42nd World Congress of Endourology and Uro-Technology (WCET).
Upcoming Meetings and Events
- UBS Global Healthcare Conference – November 10–13, 2025, in Palm Beach Gardens, Florida. EDAP management will participate in one-on-one meetings with investors.
- Jefferies London Healthcare Conference – November 18–20, 2025, in London, U.K. EDAP management will present on Tuesday, November 18, from 4:30–4:55 p.m. GMT.
- Piper Sandler 37th Annual Healthcare Conference – December 2–4, 2025, in New York, New York. EDAP management will present on Tuesday, December 2, at 10:30–10:55 a.m. ET.
2025 Financial Guidance
The Company is reiterating its 2025 financial guidance. Core HIFU business revenue is expected to grow within the range of
Third Quarter 2025 Results
High-Intensity Focused Ultrasound (HIFU) Business
Total revenue in the HIFU business for the third quarter of 2025 was
Non-Core Businesses (ESWL and Distribution)
Total revenue from the Company’s non-core businesses for the third quarter of 2025 was
Company
Total worldwide revenue for the third quarter of 2025 was
Gross profit for the third quarter of 2025 was
Operating expenses for the third quarter of 2025 were stable at
Operating loss for the third quarter of 2025 was
Net loss for the third quarter of 2025 was
Year-to-Date Results
High-Intensity Focused Ultrasound (HIFU) Business
Total revenue in the HIFU business for the nine months ended September 30, 2025, was
Non-Core Businesses (ESWL and Distribution)
Total revenue from the Company’s non-core businesses for the nine months ended September 30, 2025, was
Company
Total worldwide revenue for the nine months ended September 30, 2025, was
Gross profit for the nine months ended September 30, 2025, was
Operating expenses for the nine months ended September 30, 2025, totaled
Operating loss for the nine months ended September 30, 2025, was
Net loss for the nine months ended September 30, 2025, was
As of September 30, 2025, the Company held cash and cash equivalents of
Conference Call Information
A conference call and webcast to discuss the third quarter 2025 financial results will be hosted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.
Date: Thursday, November 6th @ 8:30am Eastern Time
Domestic: 1-800-274-8461
International: 1-203-518-9814
Passcode (Conf ID): EDAP
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1738018&tp_key=c91765d4a0
About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as “believe,” “can,” “contemplate,” “could,” “plan,” “intend,” “is designed to,” “may,” “might,” “potential,” “objective,” “target,” “project,” “predict,” “forecast,” “ambition,” “guideline,” “should,” “will,” “estimate,” “expect” and “anticipate,” or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services. Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete.
Investor Contacts
Investor Relations
EDAP TMS SA
investor.relations@focalone.com
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com
EDAP TMS S.A.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands of Euros and U.S. Dollars, except per share data)
| | | | | | | | | |
| | | Three Months Ended: | | Three Months Ended: | ||||
| | September 30, | September 30, | September 30, | September 30, | ||||
| | | 2025 | | 2024 | | 2025 | | 2024 |
| | | Euros | | Euros | | $US | | $US |
| Sales of medical equipment | 9,430 | 8,393 | 10,958 | 9,240 | ||||
| Net sales of RPP and leases | 2,194 | 1,586 | 2,550 | 1,746 | ||||
| Sales of spare parts, supplies and services | 2,255 | 3,120 | 2,621 | 3,435 | ||||
| TOTAL REVENUES | 13,879 | 13,098 | 16,128 | 14,420 | ||||
| Cost of sales | (7,908) | (7,944) | (9,189) | (8,746) | ||||
| GROSS PROFIT | 5,972 | 5,154 | 6,939 | 5,675 | ||||
| Research & development expenses | (2,086) | (1,716) | (2,424) | (1,889) | ||||
| Selling, general & administrative expenses | (8,811) | (9,271) | (10,239) | (10,207) | ||||
| Total operating expenses | (10,898) | (10,987) | (12,663) | (12,096) | ||||
| OPERATING LOSS | (4,926) | (5,833) | (5,724) | (6,422) | ||||
| Interest (expense) income, net | (49) | 102 | (57) | 113 | ||||
| Currency exchange gains (loss), net | 64 | (606) | 75 | (667) | ||||
| LOSS BEFORE INCOME TAXES | (4,911) | (6,337) | (5,707) | (6,976) | ||||
| Income tax (expense) credit, net | (103) | (62) | (120) | (69) | ||||
| NET LOSS | (5,014) | (6,399) | (5,827) | (7,045) | ||||
| Earning per share – basic and diluted | (0.13) | (0.17) | (0.16) | (0.19) | ||||
| Average number of shares used in computation of basic and diluted EPS | 37,438,630 | 37,233,406 | 37,438,630 | 37,233,406 | ||||
NOTE: Translated for convenience of the reader to U.S. dollars at the 2025 average three months’exchange rate of 1 Euro = 1.1620 USD, and 2024 average three months’exchange rate of 1 Euro = 1.1010 USD
EDAP TMS S.A.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands of Euros and U.S. Dollars, except per share data)
| | | | | | | | | |
| | | Nine Months Ended: | | Nine Months Ended: | ||||
| | September 30, | September 30, | September 30, | September 30, | ||||
| | | 2025 | | 2024 | | 2025 | | 2024 |
| | | Euros | | Euros | | $US | | $US |
| Sales of medical equipment | 29,614 | 29,478 | 33,207 | 32,006 | ||||
| Net sales of RPP and leases | 6,600 | 5,247 | 7,401 | 5,697 | ||||
| Sales of spare parts, supplies and services | 7,267 | 9,072 | 8,148 | 9,850 | ||||
| TOTAL REVENUES | 43,480 | 43,797 | 48,755 | 47,553 | ||||
| Cost of sales | (24,992) | (26,338) | (28,024) | (28,597) | ||||
| GROSS PROFIT | 18,488 | 17,458 | 20,732 | 18,956 | ||||
| Research & development expenses | (6,749) | (5,862) | (7,568) | (6,364) | ||||
| Selling, general & administrative expenses | (28,430) | (28,393) | (31,879) | (30,828) | ||||
| Total operating expenses | (35,179) | (34,254) | (39,448) | (37,192) | ||||
| OPERATING LOSS | (16,691) | (16,796) | (18,716) | (18,236) | ||||
| Interest (expense) income, net | (92) | 438 | (104) | 475 | ||||
| Currency exchange gains (loss), net | (572) | (419) | (642) | (455) | ||||
| LOSS BEFORE INCOME TAXES | (17,355) | (16,777) | (19,461) | (18,216) | ||||
| Income tax (expense) credit, net | (333) | (300) | (374) | (326) | ||||
| NET LOSS | (17,689) | (17,077) | (19,835) | (18,542) | ||||
| Earning per share – basic and diluted | (0.47) | (0.46) | (0.53) | (0.50) | ||||
| Average number of shares used in computation of basic and diluted EPS | 37,417,439 | 37,149,121 | 37,417,439 | 37,149,121 | ||||
NOTE: Translated for convenience of the reader to U.S. dollars at the 2025 average nine months’ exchange rate of 1 Euro = 1.1213 USD, and 2024 average nine months’ exchange rate of 1 Euro = 1.0858 USD
EDAP TMS S.A.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands of Euros and U.S. Dollars)
| | | | | | | | | |
| | September 30, | December 31, | September 30, | December 31, | ||||
| | | 2025 | | 2024 | | 2025 | | 2024 |
| | | Euros | | Euros | | $US | | $US |
| Cash, cash equivalents and short-term investments | 10,567 | 29,836 | 12,400 | 30,883 | ||||
| Accounts receivable, net | 19,025 | 20,288 | 22,325 | 21,000 | ||||
| Inventory | 13,799 | 18,495 | 16,193 | 19,143 | ||||
| Other current assets | 960 | 1,258 | 1,127 | 1,302 | ||||
| TOTAL CURRENT ASSETS | 44,352 | 69,876 | 52,044 | 72,328 | ||||
| Property, plant and equipment, net | 10,016 | 10,336 | 11,753 | 10,699 | ||||
| Goodwill | 2,412 | 2,412 | 2,830 | 2,496 | ||||
| Other non-current assets | 4,685 | 3,439 | 5,498 | 3,560 | ||||
| TOTAL ASSETS | 61,464 | 86,063 | 72,124 | 89,083 | ||||
| Accounts payable & other accrued liabilities | 16,844 | 21,350 | 19,765 | 22,099 | ||||
| Deferred revenues, current portion | 6,372 | 6,641 | 7,477 | 6,874 | ||||
| Short term borrowing | 5,048 | 6,243 | 5,924 | 6,462 | ||||
| Other current liabilities | 3,140 | 3,577 | 3,685 | 3,702 | ||||
| TOTAL CURRENT LIABILITIES | 31,404 | 37,811 | 36,851 | 39,138 | ||||
| Obligations under operating and finance leases non-current | 1,495 | 1,939 | 1,754 | 2,007 | ||||
| Long-term debt, non-current | 1,009 | 2,162 | 1,183 | 2,238 | ||||
| Deferred revenues, non-current | 1,202 | 358 | 1,411 | 370 | ||||
| Other long-term liabilities | 3,034 | 2,897 | 3,560 | 2,999 | ||||
| TOTAL LIABILITIES | 38,144 | 45,167 | 44,759 | 46,752 | ||||
| TOTAL SHAREHOLDERS’EQUITY | 23,321 | 40,896 | 27,365 | 42,331 | ||||
| TOTAL LIABILITIES & SHAREHOLDERS’ EQUITY | 61,464 | 86,063 | 72,124 | 89,083 |
NOTE: Translated for convenience of the reader to U.S. dollars at the exchange rate of 1 Euro = 1.1734 USD, on September 30, 2025 and at the exchange rate of 1 Euro = 1.0351 USD, on December 31, 2024.
EDAP TMS S.A.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands of Euros and U.S. Dollars)
| | | | | | | | | |
| | Nine Months Ended | Twelve Months Ended | Nine Months Ended | Twelve Months Ended | ||||
| | | September 30, | | December 31, | | September 30, | | December 31, |
| | | 2025 | | 2024 | | 2025 | | 2024 |
| | | (Euros) | | (Euros) | | ($US) | | ($US) |
| NET INCOME (LOSS) | (17,689) | (19,018) | (19,835) | (20,520) | ||||
| Adjustments to reconcile net income (loss) to net cash generated by (used in) operating activities(1) | 4,591 | 7,395 | 5,148 | 7,979 | ||||
| OPERATING CASH FLOW | (13,098) | (11,623) | (14,687) | (12,541) | ||||
| Increase/Decrease in operating assets and liabilities | 625 | (1,961) | 701 | (2,116) | ||||
| NET CASH GENERATED BY (USED IN) OPERATING ACTIVITIES | (12,473) | (13,584) | (13,986) | (14,657) | ||||
| Additions to capitalized assets produced by the company and other capital expenditures | (3,577) | (4,120) | (4,011) | (4,445) | ||||
| NET CASH GENERATED BY (USED IN) INVESTING ACTIVITIES | (3,577) | (4,120) | (4,011) | (4,445) | ||||
| NET CASH GENERATED BY (USED IN) FINANCING ACTIVITIES | (2,545) | 4,635 | (2,854) | 5,001 | ||||
| NET EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS | (673) | (566) | 2,369 | (3,103) | ||||
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | (19,268) | (13,635) | (18,483) | (17,204) |
(1) including share based compensation expenses for 1,560 thousand of Euros for the nine months ended September 30, 2025 and 3,283 thousand of Euros for the full year ended December 31, 2024.
NOTE: Translated for convenience of the reader to U.S. dollars at the 2025 average nine months’ exchange rate of 1 Euro = 1.1213 USD, and 2024 average twelve months exchange rate of 1 Euro = 1.0790 USD
EDAP TMS S.A.
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION
nine months ended September 30, 2025
(Amounts in thousands of Euros)
| | | | | | | | | | | | | | | | | | | | |
| | HIFU | ESWL | Distribution | Reconciling | Total After | ||||||||||||||
| | | Division | | | | Division | | | | Division | | | | Items | | Consolidation | | | |
| Sales of medical equipment | 13,479 | 1,299 | 14,835 | — | 29,614 | | |||||||||||||
| Net sales of RPP and leases | 5,645 | 749 | 206 | — | 6,600 | | |||||||||||||
| Sales of spare parts, supplies and services | 2,182 | 3,058 | 2,027 | — | 7,267 | | |||||||||||||
| TOTAL REVENUES | 21,306 | 5,106 | 17,068 | — | 43,480 | | |||||||||||||
| GROSS PROFIT (% of Net Sales) | 10,428 | 48.9 | % | 2,253 | 44.1 | % | 5,807 | 34.0 | % | — | 18,488 | 42.5 | % | ||||||
| Research & development expenses | (6,213) | (118) | (419) | — | (6,749) | | |||||||||||||
| Selling, general & administrative expenses | (18,979) | (777) | (5,889) | (2,786) | (28,430) | | |||||||||||||
| OPERATING PROFIT (LOSS) | (14,763) | 1,358 | (500) | (2,786) | (16,691) | |
Attachment
FAQ
What were EDAP (EDAP) Q3 2025 total revenues and growth?
How much did EDAP's HIFU revenue grow in Q3 2025 for EDAP?
What drove EDAP's Q3 2025 revenue improvement (EDAP)?
What financing did EDAP announce on November 6, 2025?
What is EDAP's guidance for 2025 core HIFU revenue?
How did EDAP's cash position change by September 30, 2025?
